#Germany #Berlin #Lutetium-177 #Eckert Ziegler #AtomVie

Eckert Ziegler and AtomVie Global Radiopharma's New Collaboration

On March 20, 2025, a groundbreaking partnership was announced between Eckert Ziegler SE and AtomVie Global Radiopharma Inc., marking a significant milestone in the radiopharmaceutical industry. The agreement primarily revolves around the global supply of Lutetium-177, a radioisotope crucial for developing advanced therapies in nuclear medicine.

Overview of the Agreement

This strategic collaboration encompasses both the early and late stages of product development, extending to various global programs aimed at enhancing the efficacy and availability of radiopharmaceuticals. Eckert Ziegler, known for its high-quality Theralugand® Lutetium-177, will support AtomVie’s manufacturing and contract development activities, ensuring that effective medical treatments are accessible worldwide.

The flexibility embedded within the agreement is especially noteworthy. It allows AtomVie to adapt dynamically to the diverse needs of their pharmaceutical partners, addressing the various stages of product development and commercialization, while also complying with strict regulatory standards globally.

Statements from Leadership

The collaboration has received positive remarks from key executives. Dr. Harald Hasselmann, CEO of Eckert Ziegler, expressed enthusiasm about the partnership, stating, “We are pleased to support AtomVie in advancing their global radiopharmaceutical development programs using Theralugand®. By providing our high-quality radionuclides, we play an essential role in fostering innovative therapeutic approaches within nuclear medicine.”

Adding to this sentiment, Bruno Paquin, CEO of AtomVie, highlighted the importance of the partnership by indicating that it is critical for ensuring their global partners developing Lutetium-177-based radiopharmaceuticals have the necessary support. He mentioned, “With the opening of our new facility expected this year, this collaboration strengthens our capacity to offer reliable, high-quality manufacturing services. Together with our partners, we look forward to advancing innovation and transforming patients' lives.”

Significance of This Partnership

The agreement has profound implications for the medical community. Eckert Ziegler stands as a leading specialist in isotope-based components for nuclear medicine, providing a wide range of products and services from developmental phases to manufacturing and distribution. Their inclusion of Lutetium-177 into AtomVie’s portfolio promises to enhance treatment options available to patients with serious conditions.

Moreover, AtomVie Global Radiopharma Inc. is recognized as a premier contract development and manufacturing organization specializing in the global distribution of clinical and commercial radiopharmaceutical products. The organization's extensive suite of scientific, regulatory, technical, quality, and logistical services is geared toward supporting clients engaged in studies across over 25 nations worldwide.

As these two companies combine efforts, the future of radiopharmaceuticals appears increasingly robust, addressing patient needs globally with innovative treatment alternatives. The partnership signifies not just a business transaction but a commitment to advancing healthcare and providing efficient, accessible medical solutions.

In conclusion, the union of Eckert Ziegler and AtomVie reflects the industry's ongoing evolution toward collaborative efforts to tackle healthcare challenges through the development of advanced radiopharmaceutical products. The partnership is poised to revolutionize treatment protocols in nuclear medicine and improve patient outcomes across various demographics.

For further details, visit Eckert Ziegler and AtomVie.